Cargando…
Gene expression‐based drug repurposing to target aging
Aging is the largest risk factor for a variety of noncommunicable diseases. Model organism studies have shown that genetic and chemical perturbations can extend both lifespan and healthspan. Aging is a complex process, with parallel and interacting mechanisms contributing to its aetiology, posing a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156541/ https://www.ncbi.nlm.nih.gov/pubmed/29959820 http://dx.doi.org/10.1111/acel.12819 |
_version_ | 1783358126824620032 |
---|---|
author | Dönertaş, Handan Melike Fuentealba Valenzuela, Matías Partridge, Linda Thornton, Janet M. |
author_facet | Dönertaş, Handan Melike Fuentealba Valenzuela, Matías Partridge, Linda Thornton, Janet M. |
author_sort | Dönertaş, Handan Melike |
collection | PubMed |
description | Aging is the largest risk factor for a variety of noncommunicable diseases. Model organism studies have shown that genetic and chemical perturbations can extend both lifespan and healthspan. Aging is a complex process, with parallel and interacting mechanisms contributing to its aetiology, posing a challenge for the discovery of new pharmacological candidates to ameliorate its effects. In this study, instead of a target‐centric approach, we adopt a systems level drug repurposing methodology to discover drugs that could combat aging in human brain. Using multiple gene expression data sets from brain tissue, taken from patients of different ages, we first identified the expression changes that characterize aging. Then, we compared these changes in gene expression with drug‐perturbed expression profiles in the Connectivity Map. We thus identified 24 drugs with significantly associated changes. Some of these drugs may function as antiaging drugs by reversing the detrimental changes that occur during aging, others by mimicking the cellular defence mechanisms. The drugs that we identified included significant number of already identified prolongevity drugs, indicating that the method can discover de novo drugs that meliorate aging. The approach has the advantages that using data from human brain aging data, it focuses on processes relevant in human aging and that it is unbiased, making it possible to discover new targets for aging studies. |
format | Online Article Text |
id | pubmed-6156541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61565412018-10-01 Gene expression‐based drug repurposing to target aging Dönertaş, Handan Melike Fuentealba Valenzuela, Matías Partridge, Linda Thornton, Janet M. Aging Cell Original Papers Aging is the largest risk factor for a variety of noncommunicable diseases. Model organism studies have shown that genetic and chemical perturbations can extend both lifespan and healthspan. Aging is a complex process, with parallel and interacting mechanisms contributing to its aetiology, posing a challenge for the discovery of new pharmacological candidates to ameliorate its effects. In this study, instead of a target‐centric approach, we adopt a systems level drug repurposing methodology to discover drugs that could combat aging in human brain. Using multiple gene expression data sets from brain tissue, taken from patients of different ages, we first identified the expression changes that characterize aging. Then, we compared these changes in gene expression with drug‐perturbed expression profiles in the Connectivity Map. We thus identified 24 drugs with significantly associated changes. Some of these drugs may function as antiaging drugs by reversing the detrimental changes that occur during aging, others by mimicking the cellular defence mechanisms. The drugs that we identified included significant number of already identified prolongevity drugs, indicating that the method can discover de novo drugs that meliorate aging. The approach has the advantages that using data from human brain aging data, it focuses on processes relevant in human aging and that it is unbiased, making it possible to discover new targets for aging studies. John Wiley and Sons Inc. 2018-08-09 2018-10 /pmc/articles/PMC6156541/ /pubmed/29959820 http://dx.doi.org/10.1111/acel.12819 Text en © 2018 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Papers Dönertaş, Handan Melike Fuentealba Valenzuela, Matías Partridge, Linda Thornton, Janet M. Gene expression‐based drug repurposing to target aging |
title | Gene expression‐based drug repurposing to target aging |
title_full | Gene expression‐based drug repurposing to target aging |
title_fullStr | Gene expression‐based drug repurposing to target aging |
title_full_unstemmed | Gene expression‐based drug repurposing to target aging |
title_short | Gene expression‐based drug repurposing to target aging |
title_sort | gene expression‐based drug repurposing to target aging |
topic | Original Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156541/ https://www.ncbi.nlm.nih.gov/pubmed/29959820 http://dx.doi.org/10.1111/acel.12819 |
work_keys_str_mv | AT donertashandanmelike geneexpressionbaseddrugrepurposingtotargetaging AT fuentealbavalenzuelamatias geneexpressionbaseddrugrepurposingtotargetaging AT partridgelinda geneexpressionbaseddrugrepurposingtotargetaging AT thorntonjanetm geneexpressionbaseddrugrepurposingtotargetaging |